BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C

Nov 4, 2024
1 min read

CEO Elias Papatheodorou describes the unmet need in liver disease and the rationale for MKK4, a target HepaRegeniX is focused on and is based on work by Professor Lars Zender University Hospital, Tübingen, Germany.

https://vimeo.com/1026063375

Brought to you by

Recent Posts

See All

Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads

Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month

San Diego based Replicate Bioscience believes that self-replicating RNA (srRNA) has key advantages over linear or circular RNA. Last year Novo signed on as a partner in obesity and diabetes

BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight